Moderna vs Neurocrine Biosciences: revenue, profit, margins and growth compared
Moderna brought in $1.9B of revenue in fiscal 2025, Neurocrine Biosciences $2.9B in fiscal 2025. Revenue changed by -39.9% at Moderna and +21.4% at Neurocrine Biosciences on the year before, so Neurocrine Biosciences grew faster. Moderna kept -145.2% of its revenue as net profit, Neurocrine Biosciences 16.7%. Free cash flow was -$2.1B at Moderna and $748.7M at Neurocrine Biosciences.
Fiscal years as each company reports them; the two may end in different months.
Questions about Moderna and Neurocrine Biosciences
Which is bigger by revenue, Moderna or Neurocrine Biosciences?
Neurocrine Biosciences is bigger by revenue: $2.9B in fiscal 2025, against $1.9B for Moderna in fiscal 2025.
Which keeps more of its revenue as profit, Moderna or Neurocrine Biosciences?
Moderna had a net margin of -145.2% in fiscal 2025; Neurocrine Biosciences had 16.7% in fiscal 2025.
Which grew revenue faster, Moderna or Neurocrine Biosciences?
In their latest fiscal years revenue changed by -39.9% at Moderna and +21.4% at Neurocrine Biosciences.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.